CERT2
Cardiovascular Risk Assessment
CommercialActive
Key Facts
About Zora Biosciences
Zora Biosciences is a privately held, commercial-stage diagnostics company based in Espoo, Finland, founded in 2007. The company has developed a proprietary mass spectrometry platform to identify ceramide and phospholipid biomarkers for cardiometabolic risk assessment. Its flagship products, CERT2 for cardiovascular risk and dSCORE for type 2 diabetes risk, are validated and available, with a test for fatty liver disease in development. Zora's strategy leverages partnerships, including with Mayo Clinic, and its own lab services to drive adoption of its novel risk stratification tools.
View full company profileTherapeutic Areas
Other Cardiovascular Risk Assessment Drugs
| Drug | Company | Phase |
|---|---|---|
| LDL-c direct FS | DiaSys Diagnostic Systems | Launched |
| AXINON® LDL-p Test System | Numares Health | Approved |
| AXINON® lipoFIT® | Numares Health | Approved |